Send to

Choose Destination
PLoS Comput Biol. 2009 Nov;5(11):e1000557. doi: 10.1371/journal.pcbi.1000557. Epub 2009 Nov 6.

Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

Author information

Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.

Erratum in

  • PLoS Comput Biol. 2009 Dec;5(12). doi: 10.1371/annotation/d5844bf3-a6ed-4221-a7ba-02503405cd5e.


The discovery of small molecules targeted to specific oncogenic pathways has revolutionized anti-cancer therapy. However, such therapy often fails due to the evolution of acquired resistance. One long-standing question in clinical cancer research is the identification of optimum therapeutic administration strategies so that the risk of resistance is minimized. In this paper, we investigate optimal drug dosing schedules to prevent, or at least delay, the emergence of resistance. We design and analyze a stochastic mathematical model describing the evolutionary dynamics of a tumor cell population during therapy. We consider drug resistance emerging due to a single (epi)genetic alteration and calculate the probability of resistance arising during specific dosing strategies. We then optimize treatment protocols such that the risk of resistance is minimal while considering drug toxicity and side effects as constraints. Our methodology can be used to identify optimum drug administration schedules to avoid resistance conferred by one (epi)genetic alteration for any cancer and treatment type.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center